FDA Clears
First Topical Form of Minocycline for Acne, i.e. 4% minocycline topical foam
(Amzeeq, Foamix Pharmaceuticals) to treat inflammatory lesions of nonnodular
moderate to severe acne vulgaris in adults and in children aged 9 years or
older.
الأربعاء، أكتوبر 30
الاثنين، أكتوبر 14
Breaking news
In this month, October 2019, the US-FDA has approved trifarotene cream 0.005% (Aklief, Galderma), as the first new retinoid molecule to be approved in >20 years for the once-daily topical treatment of acne vulgaris, both facial (forehead, cheeks, nose, and chin) and truncal (chest, shoulders, and back), in patients aged 9 years or older.
Trifarotene is the only topical retinoid that selectively targets retinoic acid receptor (RAR) gamma, the most common RAR found in the skin.
الثلاثاء، أكتوبر 1
الاشتراك في:
الرسائل (Atom)